Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272745 | 0.82 | S1PR1 (0.35) | FPR2NLRP3 | |
| SCHEMBL16335188 | 0.81 | FPR2 (0.31) | FPR2 | |
| SCHEMBL9899452 | 0.81 | FPR2 (0.34) | FPR2NLRP3 | |
| SCHEMBL17859390 | 0.74 | CYP1A2 (0.34) | NLRP3 | |
| Hydrochloric Acid SCHEMBL26601129 | 0.71 | — | — | |
| SCHEMBL18214733 | 0.71 | ENPP3 (0.35) | FPR2NLRP3 | |
| SCHEMBL9901605 | 0.71 | FPR2 (0.49) | FPR2 | |
| SCHEMBL10223201 | 0.69 | NLRP3 (0.35) | NLRP3 | |
| SCHEMBL3713594 | 0.69 | CCR4 (0.33) | — | |
| SCHEMBL19564473 | 0.67 | NLRP3 (0.32) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2012077051-A1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267569-A1 | Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists | ADORA1, ADORA3, HCAR3 | FPR2 333/4885NLRP3 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.